Project description:Mesenchymal stromal cells are a potential therapeutic for Acute Respiratory Distress Syndrome due to COVID-19, with pleiotropic immunomodulatory and reparative properties.This study investigated the safety and efficacy of ORBCEL-C (CD362 enriched umbilical cord-derived Mesenchymal Stromal Cells) in this patient population.
Project description:Mechanisms underlying paediatric acute respiratory distress syndrome (PARDS) remain poorly understood, limiting advances in diagnosis and treatment. To address this gap, we adopted a high-dimensional multi-omics approach to better understand immune dysregulation in PARDS, aiming to identify distinct pathogenic pathways. We show that severe PARDS is marked by interferon-driven immune dysregulation, with pulmonary T cells and myeloid cells exhibiting strong interferon responses and suppressed IL-1 pathways, resulting in impaired immune cell function and reduced IL-1α/β levels.